Insmed reported $-122459000 in EBIT for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
DBV Technologies DBVT:US USD -18020000 5.8M
Acelrx Pharmaceuticals ACRX:US USD -6632000 2.04M
Alimera Sciences ALIM:US USD -3411000 1.44M
Biomarin Pharmaceutical BMRN:US USD 2.38M 36.77M
Cytokinetics CYTK:US USD -108441000 97.57M
Gilead Sciences GILD:US USD 2.81B 784M
Insmed INSM:US USD -122459000 21.52M
Mirati Therapeutics MRTX:US USD -186443000 9.24M
Novartis NVS:US USD 3.33B 8M
Regeneron Pharmaceuticals REGN:US USD 1.22B 83.2M
Sarepta Therapeutics SRPT:US USD -131355000 79.78M
Seattle Genetics SGEN:US USD -192805000 59.69M
Ultragenyx Pharmaceutical RARE:US USD -225066000 83.47M
Vertex Pharmaceuticals VRTX:US USD 1.13B 7.4M